Apr. 22 at 5:11 PM
$CALC NO EVIDENCE of drug related toxicity in P2 KOURAGE TRIAL...Auxora advances toward pivotal program in acute pancreatitis.....Trial design and FDA acceptance by June 30...This would represent the first U.S pivotal program evaluating a therapeutic drug for AP....The company continues to advance a second channel inhibitor in pulmonary arterial hypertension following positive preclinical data.....Auxora in AP demonstrated clinically meaningful results with improvement in organ failure with statiscally significant 100% reduction new onset severe respiratory failure with excellent toleration....CM5480 restored or improved heart contraction and cardiac output, DNA repair, and significantly reduced right ventricular dysfunction....CALC holds a treasury of cardiovascular therapies and represents a great investment opportunity as the future looks very promising all contingent on finding financing, acquiring partnership or sale of the company......JMO
